Literature DB >> 20615923

Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas.

Felipe Andreiuolo1, Stéphanie Puget, Matthieu Peyre, Carmela Dantas-Barbosa, Nathalie Boddaert, Cathy Philippe, Audrey Mauguen, Jacques Grill, Pascale Varlet.   

Abstract

Ependymomas are glial neoplasms occurring in any location throughout the central nervous system and supposedly are derived from radial glia cells. Recent data suggest that these tumors may have different biological and clinical behaviors according to their location. Pediatric supratentorial and infratentorial ependymoma (SE and IE) were compared with respect to clinical and radiological parameters and immunohistochemistry (IHC). Neuronal markers were specifically assessed by IHC and quantitative PCR (qPCR). No single morphological or radiological characteristic was associated with location or any neuronal marker. However, there was a significant overexpression of neuronal markers in SE compared with IE: neurofilament light polypeptide 70 (NEFL)-positive tumor cells were found in 23 of 34 SE and in only 4 of 32 IE (P < .001). Among SE, 10 of 34 exhibited high expression of NEFL, defined as more than 5% positive cells. qPCR confirmed the upregulation of neuronal markers (NEFL, LHX2, FOXG1, TLX1, and NPTXR) in SE compared with IE. In addition, strong NEFL expression in SE was correlated with better progression-free survival (P = .007). Our results support the distinction of SE and IE. SEs are characterized by neuronal differentiation, which seems to be associated with better prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20615923      PMCID: PMC3098029          DOI: 10.1093/neuonc/noq074

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  32 in total

1.  Ganglioglioma with a tanycytic ependymoma as the glial component.

Authors:  S Hayashi; S Kameyama; M Fukuda; H Takahashi
Journal:  Acta Neuropathol       Date:  2000-03       Impact factor: 17.088

2.  The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2.

Authors:  Q Zhou; G Choi; D J Anderson
Journal:  Neuron       Date:  2001-09-13       Impact factor: 17.173

3.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.

Authors:  J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Prognostic factors in intracranial ependymomas in children.

Authors:  D Figarella-Branger; M Civatte; C Bouvier-Labit; J Gouvernet; D Gambarelli; J C Gentet; G Lena; M Choux; J F Pellissier
Journal:  J Neurosurg       Date:  2000-10       Impact factor: 5.115

5.  Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49.

Authors:  D C Dodds; I A Omeis; S J Cushman; J A Helms; M S Perin
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

6.  Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.

Authors:  Josef Zamecnik; Matija Snuderl; Tomas Eckschlager; Marketa Chanova; Marie Hladikova; Michal Tichy; Roman Kodet
Journal:  Mod Pathol       Date:  2003-10       Impact factor: 7.842

7.  Specific alternative HOX11 transcripts are expressed in paediatric neural tumours and T-cell acute lymphoblastic leukaemia.

Authors:  Paul M Watt; Katrin Hoffmann; Wayne K Greene; Rachael L Brake; Jette Ford; Ursula R Kees
Journal:  Gene       Date:  2003-12-24       Impact factor: 3.688

8.  Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.

Authors:  Hideaki Yokoo; Sumihito Nobusawa; Hirohide Takebayashi; Kazuhiro Ikenaka; Koji Isoda; Makoto Kamiya; Atsushi Sasaki; Junko Hirato; Yoichi Nakazato
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  Intracranial ependymomas of childhood: long-term outcome and prognostic factors.

Authors:  I F Pollack; P C Gerszten; A J Martinez; K H Lo; B Shultz; A L Albright; J Janosky; M Deutsch
Journal:  Neurosurgery       Date:  1995-10       Impact factor: 4.654

10.  Orphan nuclear receptor TLX activates Wnt/beta-catenin signalling to stimulate neural stem cell proliferation and self-renewal.

Authors:  Qiuhao Qu; Guoqiang Sun; Wenwu Li; Su Yang; Peng Ye; Chunnian Zhao; Ruth T Yu; Fred H Gage; Ronald M Evans; Yanhong Shi
Journal:  Nat Cell Biol       Date:  2009-12-13       Impact factor: 28.824

View more
  23 in total

Review 1.  Genetic differences on intracranial versus spinal cord ependymal tumors: a meta-analysis of genetic researches.

Authors:  Chang-Hyun Lee; Chun Kee Chung; Chi Heon Kim
Journal:  Eur Spine J       Date:  2016-09-16       Impact factor: 3.134

2.  Proteomic and Mitochondrial Genomic Analyses of Pediatric Brain Tumors.

Authors:  Brenda Luna; Sanjiv Bhatia; Changwon Yoo; Quentin Felty; David I Sandberg; Michael Duchowny; Ziad Khatib; Ian Miller; John Ragheb; Jayakar Prasanna; Deodutta Roy
Journal:  Mol Neurobiol       Date:  2014-10-25       Impact factor: 5.590

3.  A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.

Authors:  Till Milde; Susanne Kleber; Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Philipp Koch; Hans-Georg Kopp; Manfred Jugold; Hedwig E Deubzer; Ina Oehme; Marco Lodrini; Hermann-Josef Gröne; Axel Benner; Oliver Brüstle; Richard J Gilbertson; Andreas von Deimling; Andreas E Kulozik; Stefan M Pfister; Ana Martin-Villalba; Olaf Witt
Journal:  Acta Neuropathol       Date:  2011-08-24       Impact factor: 17.088

4.  Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling.

Authors:  Dominique Figarella-Branger; Emmanuèle Lechapt-Zalcman; Emeline Tabouret; Stephanie Jünger; André Maues de Paula; Corinne Bouvier; Carole Colin; Anne Jouvet; Fabien Forest; Felipe Andreiuolo; Isabelle Quintin-Roue; Marie-Christine Machet; Anne Heitzmann; Serge Milin; Henri Sevestre; Catherine Godfraind; François Labrousse; Philippe Metellus; Didier Scavarda; Torsten Pietsch
Journal:  Neuro Oncol       Date:  2016-03-15       Impact factor: 12.300

5.  Extraventricular anaplastic ependymoma with metastasis to scalp and neck.

Authors:  Matthew J Davis; Fauzia Hasan; Ilan Weinreb; M Christopher Wallace; Tim-Rasmus Kiehl
Journal:  J Neurooncol       Date:  2011-01-11       Impact factor: 4.130

6.  A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma.

Authors:  Ian David Connolly; Yingmei Li; Wenying Pan; Eli Johnson; Linya You; Hannes Vogel; John Ratliff; Melanie Hayden Gephart
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

7.  Supratentorial ependymoma: disease control, complications, and functional outcomes after irradiation.

Authors:  Efrat Landau; Frederick A Boop; Heather M Conklin; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-11       Impact factor: 7.038

8.  Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression.

Authors:  Christian Hagel; András Treszl; Julia Fehlert; Jonas Harder; Franziska von Haxthausen; Meike Kern; André O von Bueren; Uwe Kordes
Journal:  J Neurooncol       Date:  2013-01-31       Impact factor: 4.130

Review 9.  The fine structure of ependymomas.

Authors:  Stavros J Baloyannis; Ioannis S Baloyannis
Journal:  CNS Oncol       Date:  2014-01

10.  Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trial.

Authors:  Rajkumar Venkatramani; Lingyun Ji; Joseph Lasky; Kelley Haley; Alexander Judkins; Shengmei Zhou; Richard Sposto; Randal Olshefski; James Garvin; Tanya Tekautz; Gloria Kennedy; Shahrad Rod Rassekh; Theodore Moore; Sharon Gardner; Jeffrey Allen; Richard Shore; Christopher Moertel; Mark Atlas; Girish Dhall; Jonathan Finlay
Journal:  J Neurooncol       Date:  2013-03-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.